As the expansion and persistence of CAR T cells correlate with clinical response, we reasoned that interleukin-7 (IL-7), a pro-lymphoid growth and survival factor involved in the development, maintenance, and proliferation of T cells, would promote CAR T cell efficacy and tumor cell killing in vivo. The gene discussed is IL7; the disease is neoplasm.